EMPOWER-lung 1: A randomized, open-label, multi-national, phase

III trial of cemiplimab, a human PD-1 monoclonal antibody, versus

chemotherapy in first-line treatment of advanced non-small cell lung

cancer (NSCLC) with PD-L1 50% by Sriuranpong, V. et al.
Conclusions: HIPEC treatment can cause immunogenic changes in colorectal cancer
cells. This could explain a part of the mechanism, how HIPEC treatment may work and
inclusion of an immunotherapy may improve outcome of this treatment.
Legal entity responsible for the study: Kuno Lehmann.
Funding: Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
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Background: The therapeutic effect of oncolytic virotherapy is mediated largely by two
mechanisms; direct oncolysis due to tumor-selective viral replication and the simulta-
neous activation of innate and adaptive immune responses with the potential of long-
lasting tumor remissions. The chimeric vesicular stomatitis virus pseudotyped with
LCMV glycoprotein (VSV-GP) has been previously reported to have both a rapid lytic
cycle and a broad tumor tropism. In this study, we demonstrate its therapeutic poten-
tial in the syngeneic lung cancer model LLC1.
Methods: To address the effect of IFN sensitivity of LLC1 cells to VSV-GP mediated
oncolysis, we generated interferon receptor deficient cells (LLC1-IFNAR1-/-) using
TALENs. Therapeutic efficacy of VSV-GP was assessed in vivo in syngeneic C57BL/6
mice and athymic nude mice bearing subcutaneous tumors. The mechanisms of VSV-
GP treatment effect were investigated using bio-luminescent imaging (BLI), immuno-
histochemistry, multiplex ELISA and NanostringVR technology.
Results: The ability of VSV-GP to infect and lyse LLC1 cancer cell-lines in vitro was
abrogated by exogenously applied interferon (IFN) type I indicating a dependence of
the oncolytic effect on defects in the IFN response of cancer cells. Interferon resistance
of LLC1-IFNAR1-/- cells correlated with prolonged intratumoral viral replication and
improved therapeutic outcome in vivo, as demonstrated by using a matched pair of
LLC1 wildtype and LLC1-IFNAR-/- tumors. Additionally, BLI revealed successful
tumor-to-tumor spread of viral progeny in bilateral tumor models. VSV-GP therapy
was associated with enhanced T cell infiltration and upregulation of various immune-
associated genes. Interestingly, the efficacy of VSV-GP therapy in treating LLC1-
IFNAR-/- tumors was not diminished by the absence of CD8þ T cells and cured mice
were not immune to tumor rechallenge indicating a predominant lytic effect.
Conclusions: The treatment effect of VSV-GP in LLC1-IFNAR-/- lung cancer model is
primarily lytic with negligible contribution of adaptive immunity despite strong activa-
tion of both innate and adaptive immune signatures.
Legal entity responsible for the study: Medical University of Innsbruck.
Funding: ViraTherapeutics GmbH, Innsbruck, Austria.
Disclosure: G. Wollmann: Scientific advisor: Boehringer Ingelheim GmbH & Co. KG.
B. Spiesschaert: Part time employment: ViraTherapeutics GmbH; Part of Christian
Doppler Laboratory. F. Heinemann, B. Stierstorfer, P. Mu¨ller: Employment:
Boehringer Ingelheim GmbH & Co. KG. M. Petersson, P. Erlmann: Employment:
ViraTherapeutics GmbH. D. von Laer: Inventor of VSV-GP; Minority shares:
ViraTherapeutics GmbH (which holds the intellectual property rights for VSV-GP);
Scientific advisor: Boehringer Ingelheim. All other authors have declared no conflicts
of interest.
107TiP Phase I safety and pharmacokinetics of ADU-1604, an anti-CTLA-4
antibody, in adults with metastatic melanoma
M. Hendriks, E. de Cock, K. Maplestone, H. Namini, A. van Elsas
Clinical, Aduro Biotech Europe, Oss, Netherlands
Background: ADU-1604 is a humanized IgG1 monoclonal antibody in development
for use as monotherapy or in combination with other anti-cancer therapies. It targets a
novel epitope on the validated inhibitory receptor, CTLA-4. ADU-1604 was character-
ized in vitro and shown to bind to human CTLA-4, block binding of CD80 and CD86
to CTLA-4, and stimulate IL-2 production by activated lymphocytes. ADU-1604
enhanced T cell dependent hepatitis B surface antigen vaccine-induced antibody
responses in cynomolgus monkeys and demonstrated anti-tumor activity in a non-
small cell lung cancer patient-derived xenograft humanized mouse model. The primary
objective of the first-in-human study is to determine the recommended phase 2 dose
(RP2D) by evaluating the safety, pharmacokinetics (PK), and pharmacodynamics (PD)
of ADU-1604 administered as an intravenous (IV) infusion.
Trial design: This first-in-human, open-label, multicenter, dose-escalation study is
conducted in adults with metastatic melanoma without further established treatment
options. The study includes two parts: 1) Dose Escalation starts with 0.3 mg/kg of
ADU-1604 IV infusion in 3-6 subjects and dosing is escalated until the RP2D is defined
(represented by the dose tolerated while not exceeding the maximum tolerated dose or
maximum dose (10 mg/kg)). 2) In Dose Confirmation, 7-10 additional subjects receive
ADU-1604 at the RP2D until the maximum number of planned doses are administered
(4 treatment cycles), disease progression is confirmed, or consent is withdrawn, which-
ever occurs first. The end of the study is defined as the date when all subjects have com-
pleted the final protocol-specified safety assessment and/or discontinued study
participation. Primary endpoints include incidence of dose limiting toxicity, treat-
ment-emergent adverse events (TEAEs), and changes from baseline in safety parame-
ters. Secondary endpoints include severity of TEAEs, serious adverse events, changes
from baseline in safety assessments, serum concentration-time profiles and PK parame-
ters (including Cmax, AUC), and incidence of anti-ADU-1604 antibodies. This study is
designed to provide the RP2D of ADU-1604 based on the totality of PK-PD, as well as
clinical responses and safety.
Clinical trial identification: NCT03674502.
Legal entity responsible for the study: Aduro Biotech Europe.
Funding: Aduro Biotech Europe.
Disclosure: M. Hendriks, E. de Cock, K. Maplestone, H. Namini, A. van Elsas:
Employee of and holds stock in Aduro Biotech Europe at the time of this work.
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V. Sriuranpong1, O. Altundag2, P. Clingan3, N. Rizvi4, O. Aren Frontera5, A. Sezer6,
S. Paydas7, M. Shavdia8, I. Bondarenko9, O. Gladkov10, S. Lee11, S. Li12, P. Snodgrass11,
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Background: Most patients (pts) with NSCLC present with advanced disease at diag-
nosis. Systemic therapy with platinum-based doublet chemotherapy regimens has been
the standard first-line treatment for pts with advanced NSCLC whose tumours do not
have EGFR, ALK, or ROS 1 mutations, but there is a need for effective treatments to
improve long-term survival. With the recognition that NSCLC tumours express PD-
L1, checkpoint inhibitors are being investigated in several clinical trials. There is cur-
rently only one PD-1 inhibitor approved as monotherapy in first-line treatment of
NSCLC with PD-L1 expression50%. In a phase 1 dose escalation and NSCLC expan-
sion cohort, cemiplimab (REGN2810), a human monoclonal anti-PD-1, has demon-
strated antitumour activity with an acceptable safety profile in anti-PD-1 naı¨ve, pre-
treated pts with NSCLC.
Trial design: This is a randomised (1:1), multicentre, open-label, phase 3 study of
cemiplimab versus platinum-based doublet chemotherapy in systemic treatment-naı¨ve
pts (18 years) with stage IIIB, IIIC or IV squamous or non-squamous NSCLC whose
tumours express PD-L1 in 50% of tumour cells (NCT03088540). Pts will be stratified
by histology and geographic region. Pts will receive cemiplimab 350 mg every 3 weeks
intravenously (for up to 108 weeks) or 4–6 cycles chemotherapy with (i) paclitaxelþ
cisplatin or carboplatin, (ii) pemetrexedþ cisplatin or carboplatin with or without
pemetrexed maintenance, (iii) or gemcitabineþ cisplatin or carboplatin. The primary
objective is to evaluate progression-free survival (PFS) as determined by blinded inde-
pendent review committee. Key secondary objectives include assessment of overall sur-
vival and overall response rate. Assuming duration of study enrolment and follow-up
of 28 months and 10 months, respectively, approximately 700 randomised pts are
required to obtain 525 PFS events to yield approximately 90% power to detect a statisti-
cally significant change in median PFS between treatment arms, with the 2-sided type 1
error limited to 5%. An independent data monitoring committee will monitor safety
data during study conduct.
Editorial acknowledgement: Medical writing support under the direction of the
authors was provided by Emmanuel Ogunnowo, PhD, of Prime (Knutsford, UK) and
funded by Regeneron Pharmaceuticals, Inc. and Sanofi according to Good Publication
Practice guidelines.
Clinical trial identification: NCT03088540.
Legal entity responsible for the study: Regeneron Pharmaceutical Inc. and Sanofi.
Funding: Regeneron Pharmaceutical Inc. and Sanofi.
Disclosure: V. Sriuranpong: Honoraria for advisory board and institutional study sup-
port grants: Regeneron Pharmaceuticals, Inc. P. Clingan: Participation in clinical trial
work: MSD, AbbVie and Checkpoint Therapeutics. N. Rizvi: Personal fees: Roche,
Annals of Oncology abstracts
Volume 29 | Supplement 10 | December 2018 doi:10.1093/annonc/mdy487 | x37
D
ow
nloaded from
 https://academ
ic.oup.com
/annonc/article-abstract/29/suppl_10/m
dy487.039/5238032 by guest on 28 M
arch 2019
AstraZeneca, BMS, Merck, Novartis, Merck KGaA, Pfizer, outside the submitted work.
O. Aren Frontera: Personal fees (advisory board & lecturing): Bristol Myers Squibb,
Roche; Personal fees (lecturing): Novartis, outside the submitted work. S. Lee, S. Li, P.
Snodgrass: Employee and shareholder: Regeneron Pharmaceuticals, Inc. P. Rietschel:
Employee and shareholder, honoraria: Regeneron Pharmaceuticals, Inc. All other
authors have declared no conflicts of interest.
109TiP AcSe´ immunotherapy trials: Anti-PD-1 therapy for adult patients with
selected rare cancer types
A. Marabelle1, S. Chevret2, F. Janot3, B. Escudier4, D. Pouessel5, C. Tournigand6,
K. Hoang-Xuan7, L. Mortier8, B.J-C. Rousseau9, M.J. Schlumberger10, I.L. Ray-Coquard11,
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Background: Immune checkpoint blockade represents a major breakthrough in cancer
therapy with recent approvals of PD-1 or PD-L1 antagonist therapy in France for a
range of cancer indications. To generate high evidenced-based knowledge and to pre-
vent off-label use, the French National Cancer Institute (INCa) launched the AcSe´
Immuno-therapy Program: two exploratory phase II trials, to allow for a nationwide
safe and controlled access to nivolumab or pembrolizumab outside of their current
marketing approvals for selected rare cancer indications where the literature suggests a
potential benefit for patients, but where the difficulties of development render individ-
ual experimental studies unattractive to the pharmaceutical industry.
Trial design: The two trials, AcSe´ Nivolumab and AcSe´ Pembrolizumab are Phase 2,
single-arm, national, multicentre trials investigating the efficacy and safety of nivolu-
mab and pembrolizumab, respectively, in adult patients with specific rare cancers who
have unresectable locally advanced or metastatic disease which is resistant or refractory
to standard therapy and for whom no alternative approved or experimental treatment
options exist. Up to 650 patients will be enrolled across the two trials and assigned to
one of 13 cohorts (max. 50 patients/cohort) according to their indication (see table).
Table: 109TiP
AcSe´ nivolumab AcSe´ pembrolizumab
Cohort 1: Non-clear cell RCC Cohort 1: Rare sarcoma
Cohort 2: Rare head and neck cancer Cohort 2: Rare ovarian cancer
Cohort 3: Rare skin cancer Cohort 3: Primary CNS lymphoma
Cohort 4: MSI-H cancer (other than CRC) Cohort 4: Rare thyroid cancer
Cohort 5: Penile cancer Cohort 5: Rare malignant
neuroendocrine cancer
Cohourt 6: POLE exonuclease
domain mutated cancer
Cohort 6: Germ-cell cancer
Cohort 7: NK/T-cell lymphoma
The trials will use a two-stage Bayesian enrichment design to identify potentially sensitive
indications and assess treatment efficacy per cohort. Toxicity will also be assessed per
cohort and biological samples collected to explore the predictive factors of response and
mechanisms of acute and acquired resistance to anti-PD-1 therapy in these populations.
Legal entity responsible for the study: UNICANCER.
Funding: Institut National du Cancer (INCa), La Ligue contre le Cancer, Bristol-Myers
Squibb (BMS), MSD.
Disclosure: All authors have declared no conflicts of interest.
110TiP A phase I dose escalation trial evaluating the impact of an in situ
immunization strategy with intra-tumoral injections of Pexa-Vec in
combination with ipilimumab in advanced solid tumors with
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Background: In situ immunization is a strategy where immunomodulatory products
are injected into one tumor site in order to use the tumor as its own vaccine and to trig-
ger a systemic anti-tumor immune response. The Pexa-Vec (JX-594, Transgene) is an
oncolytic virus genetically modified to secrete GM-CSF. We formulate the hypothesis
that IT treatment with this oncolytic virus could synergize with anti-CTLA4 therapy via
oncolytic virus-induced tumor cell death & tumor-antigen release, GM-CSF-induced
recruitment/maturation/activation of antigen presenting cells, and anti-CTLA4-
induced Treg blockade/depletion and reversion of T effectors inhibition.
Trial design: ISI-JX is a multicentric, Phase I dose escalation trial followed by an exten-
sion part aiming to evaluate the safety, feasibility, and anti-tumor effects of an in situ
immunization strategy with IT injections of ipilimumab with Pexa-Vec in adults
patients (pts) with solid tumors. The trial is conducted in pts with at least one injectable
lesion (2 and8 cm) and one distant non-injected measurable target site. Pts are
treated with an IT injection of Pexa-Vec alone (1 x 109pfu) at Week 1 (W1) Day 1 (D1)
followed by 3 IT injections of Pexa-Vec (1 x 109pfu)þ ipilimumab (4 dose levels: 2.5, 5,
7.5, 10 mg/injection) at W3 D1, W5 D1 and W9 D1. Primary endpoint for escalation
part is the occurrence of Dose Limiting Toxicities (DLT) defined as the toxicities occur-
ring during the DLT assessment window (the first 5 weeks) related to Pexa-Vec,
Ipilimumab or both; and the objective response rate as per immune related Response
Criteria after 3 months of treatment for extension part. Secondary endpoints include
the disease control rate, duration of response, progression free survival and overall sur-
vival. The dose escalation part follows a classical 3þ 3 design with 3 to 6 pts at each DL
depending of the number of DTL observed (maximum of 24 pts). In the extension part,
according to on the first stage of a Gehan design, 12 patients per cohort (3) will be
enrolled (maximum of 36 pts). Up to date, the dose escalation part is ongoing: 8 pts
were enrolled (DL1 n¼ 3; DL2 n¼ 3; DL3 n¼ 2).
Editorial acknowledgement: Bidaux As & Garin G; Centre Le´on Be´rard; DRCI
Promotion Phase Pre´coce.
Clinical trial identification: EudraCT: 2014-001692-32; NCT02977156.
Legal entity responsible for the study: Centre Le´on Be´rard DRCI Promotion/Essais
Pre´coces.
Funding: Centre Le´on Be´rard & Transgene S.A.
Disclosure: All authors have declared no conflicts of interest.
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